Relmada Therapeutics (NASDAQ:RLMD) versus Minerva Neurosciences (NASDAQ:NERV) Head to Head Review

Minerva Neurosciences (NASDAQ:NERV) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Minerva Neurosciences and Relmada Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1	1	0	0	1.50
Relmada Therapeutics	1	1	4	1	2.71

Minerva Neurosciences currently has a consensus target price of $7.00, suggesting a potential upside of 14.01%. Relmada Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 83.57%. Given Relmada Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than Minerva Neurosciences.

Insider and Institutional Ownership

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are owned by institutional investors. 10.4% of Minerva Neurosciences shares are owned by company insiders. Comparatively, 20.7% of Relmada Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Minerva Neurosciences has a beta of -0.31, indicating that its stock price is 131% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Profitability

This table compares Minerva Neurosciences and Relmada Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	-41.35%	-35.62%
Relmada Therapeutics	N/A	-170.83%	-145.58%

Valuation and Earnings

This table compares Minerva Neurosciences and Relmada Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42 million	($26.80)	-0.23
Relmada Therapeutics	N/A	N/A	-$57.38 million	($1.45)	-4.51

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Relmada Therapeutics beats Minerva Neurosciences on 9 of the 12 factors compared between the two stocks.

About Minerva Neurosciences

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

About Relmada Therapeutics

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.